Core Insights - Indivior PLC has resolved its legacy U.S. Department of Justice matter by paying a total of $295 million, which eliminates a significant liability and simplifies its capital structure [1][2]. Group 1: Financial Resolution - The payment of $295 million was made using Indivior's cash on hand, leading to the termination of the resolution agreement with the DOJ [1]. - The CEO of Indivior expressed satisfaction with reaching this milestone, emphasizing the company's commitment to integrity and compliance [2]. Group 2: Company Mission and Vision - Indivior focuses on developing medicines for opioid use disorder (OUD) and aims to transform OUD into a recognized chronic disease with evidence-based treatment accessible to all patients [2]. - The company has a pipeline of product candidates designed to expand its offerings in the OUD treatment category [2].

Company Participation in Investor Events - Indivior PLC will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8th, where CEO Joe Ciaffoni and CFO Ryan Preblick will host meetings and a fireside discussion [1] - The company will also attend the H.C. Wainwright 27th Annual Global Investment Conference on September 9th, with similar meeting arrangements [2] Company Overview - Indivior is a global pharmaceutical company focused on developing medicines for opioid use disorder (OUD), aiming to transform OUD into a recognized chronic disease [3] - The company is headquartered in Richmond, VA, employs over 1,000 individuals globally, and its products are available in over 30 countries [3]

Group 1 - Indivior PLC has announced the cancellation of its secondary listing on the London Stock Exchange effective July 25, 2025, while maintaining its primary listing on the Nasdaq Stock Market [1] - An FAQ document has been prepared for shareholders regarding the London Delisting, which is accessible on the company's website [2] - Indivior is a global pharmaceutical company focused on developing medicines for opioid use disorder (OUD), aiming to transform OUD into a recognized chronic disease [3][4] Group 2 - The company has a pipeline of product candidates to expand its portfolio of OUD treatments and operates in over 30 countries worldwide [4] - Indivior is headquartered in Richmond, Virginia, and employs over 1,000 individuals globally [4]